Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.
February 18, 2020 – For the 16th consecutive year, Novo Nordisk has published its integrated 2019 Annual report detailing the company’s year-end performance.
Still accounting for financial, social and environmental performance, the Management Review details the company’s progression in fou...
Novo Nordisk has published its integrated 2018 Annual Report detailing the company’s year-end performance. The report highlights the company’s progression towards long-term targets taking an integrated approach that accounts for financial, social and environmental performance. This is the company...
Novo Nordisk, a global healthcare company specialising in diabetes, obesity and other serious chronic diseases, published its Annual Report 2017 online today at novonordisk.com/annualreport. It is the company's fourteenth integ...
Novo Nordisk has published its integrated 2015 Annual Report detailing the company’s year-end performance. The report highlights the company’s progression towards long-term targets taking an integrated approach that accounts for financial, social and environmental performance. Thi...
Novo Nordisk has joined RE100 with an ambition to use 100% renewable electricity at all its global production sites by 2020. By joining the RE100, Novo Nordisk together with more than 50 global companies, is working to increase corporate demand for renewable energy.
“Switching to renewable...
For the second straight year, the global research company Frost & Sullivan has named Novo Nordisk Indonesia the Diabetes CSR Company of the Year. The acknowledgement recognises the company’s commitment and collaboration to improve care for the six million people wi...
Next week, world leaders will launch a new round of goals, targets and indicators to pick up where the Millennium Development Goals left off. In the new issue of Novo Nordisk’s sustainability magazine – T...
Novo Nordisk stays in top of the pharmaceutical sector on the 2015 Dow Jones Sustainability World Index with a score of 81 out of a possible 100. The company’s overall score falls 3 points from 2014 and is 7 points behind Roche, the 2015 industry leader.
The 2015 ranking marks the 16t...
The Kenyan Ministry of Health, together with Novo Nordisk and the Kenya Diabetes Management and Information Centre, launched a six-month diabetes awareness campaign in Nairobi to promote early diagnosis through screening, especially among low-income populations. The ca...
For the third consecutive year, Novo Nordisk Turkey received the Turkish Ethics Award, ETÄ°KA 2014, for high ethical business conduct. The ETÄ°KA Award aims to recognise and publicly praise companies who value ethics and who are committed to operating in adherence to ethics and business morals, a...